National Institute of Allergy and Infectious Diseases (NIAID)

?? Dreaming of a career where you can make a difference? Discover the endless possibilities at NIAID with our #recruitment video. Whether you’re passionate about science, administration, or innovation, there is a place for you. Learn more from some of the dedicated public servants who make NIAID a great place to work: https://lnkd.in/e-sD2kX5 #PSRW #NIAIDCareers

A #NIAID sponsored clinical trial of an #mpox #vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to interim study results presented at #IDWeek2024. Adolescents are among the population groups affected by mpox in the current Clade I outbreak. The authors underscored the need to evaluate the vaccine in younger children to extend the evidence base to all people affected by mpox. Learn more: https://go.nih.gov/TmlJH9K Baylor College of Medicine Vanderbilt University Medical Center Saint Louis University

Research shows that the microbiome a baby has at the start of their life affects their microbiome and health as they get older. Babies born via C-section are not exposed to certain microorganisms that could have a positive effect on their long-term health. #NIH_IRP researchers, including National Institute of Allergy and Infectious Diseases (NIAID)'s Dr. Suchitra Hourigan are exploring a new practice that exposes babies born via C-sections to these microorganisms: https://go.nih.gov/LqMMhjA

Today is #NationalLatinxAIDSAwareness Day. NIAID and its partners support the #HIV response in Hispanic, Latino, and Latinx communities through research focused on prevention, testing, & treatment resources. Learn more: https://lnkd.in/d2_QUbky #NLAAD Image credit: HIVgov

Here is a digest of #NIAID-supported research presentations from Friday, October 11 at #HIVR4P2024. -Two of 11 cisgender women in African countries with #HIV continued to experience viral suppression after pausing the study treatment regimen. Characterizing their immune responses & virus samples could inform HIV science. -HIV Prevention Trials Network (HPTN) found community engagement was key to enrollment and high retention rates for transgender women in a recent #HIVprevention study. -Community stakeholders provided recommendations on how to increase community participation in the development and implementation of #HIVprevention studies in South Africa. -A study in Kalangala District, Uganda demonstrated that it was feasible to train barbers to provide an #HIVprevention intervention. Barbers participating in the intervention scored 100% on knowledge assessments. -After visiting the study site and consulting healthcare providers, several men who initially opposed their female partners’ participation in a study of injectable and oral #HIV pre-exposure prophylaxis decided to support it. -Researchers highlight how the immune responses of newborn monkeys infected with the simian version of #HIV can inform future pediatric HIV #vaccine strategies. -A protein-based #HIV vaccine platform targeting a part of the HIV surface generated a greater immune response than an mRNA-based platform in infant monkeys. -A three-step #HIV immunization strategy rapidly induced immune responses toward development of HIV broadly neutralizing antibodies in mice. -Simian-human immunodeficiency virus (SHIV) infected monkeys showed #HIV broadly neutralizing antibodies similar to the types found in humans. -Laboratory imaging displayed immune responses to particles similar to the simian version of #HIV in monkeys, which could inform the development of novel therapies and vaccines for HIV in people. -Participants in a planned #HIV treatment interruption during a study cited close health monitoring, free sexual health screenings, and being able to restart therapy any time as motivators to enroll. -An #HIV prevention study involving adolescents found sexual health knowledge empowered participants to make informed decisions about options to protect themselves from HIV. -An #HIV #vaccine concept elicited immune responses showing signs of being able to generate HIV broadly neutralizing antibodies in mice with immune systems similar to humans. For full text abstracts, visit the conference program: https://lnkd.in/d9PVgniW #HIVR4P2024 #bNAbs #HIV #HIVprevention #PrEP

We received outstanding participation and engagement during our recent codeathon to combat antimicrobial resistance (AMR), co-hosted by the National Institute of Allergy and Infectious Diseases (NIAID)! We had 60 participants that formed 10 teams with 10 countries represented. Learn more about their work: https://ow.ly/O22j50TJf12

Read a digest of #NIAID-supported research presentations from Thursday, October 10 at #HIVR4P2024. -A study found that co-locating services for #HIV pre-exposure prophylaxis and gender-affirming hormone therapy was feasible and acceptable among transgender women at 4 U.S. sites. -The monthly #dapivirine vaginal ring for #HIV prevention was safe in cisgender women who used the ring during early pregnancy and then discontinued use as soon as they learned that they were pregnant. -An #HIV #vaccine concept elicited cross-neutralizing antibodies in monkeys. -A study in mice shed light on how #vaccines can train the immune system to generate #HIV broadly neutralizing antibodies. -By examining the structure of antibodies generated by an #HIV vaccine concept in monkeys, researchers identified an opportunity to tweak future vaccine designs. -An analysis from the Phase 3 study of long-acting injectable #cabotegravir for #HIV pre-exposure prophylaxis in cisgender women found the drug did not interact with long-acting reversible contraceptive drugs. -Researchers conducted a study to illustrate the advantages of testing certain #HIV vaccine concepts in monkeys that they expose to the simian version of HIV (SHIV). For full text abstracts, visit the conference program: https://lnkd.in/d9PVgniW #HIVR4P2024 #PrEP #bNabs International AIDS Society HIV Prevention Trials Network (HPTN)

Join the NIAID Office of Research Training & Development for a virtual information session about Intramural NIAID Research Opportunities (INRO) 2025 on Thursday, October 17. The session will provide an overview of this unique one-year paid #postbaccalaureate fellowship and how to apply. Register at https://lnkd.in/eDzHXZrQ #NIAIDTraining #INRO2025

Congratulations to the 2024 recipients of The Nobel Prize in Chemistry, Drs. David Baker, Demis Hassabis and John Jumper! NIH is honored to have supported the research of Dr. David Baker (UW Medicine), who received half of the prize for his computational protein design work. His accomplishments in creating new kinds of proteins that can be used as pharmaceuticals, vaccines, nanomaterials or tiny sensors is an incredible example of the value of taxpayer investment in NIH-funded research. Read more about the winners and their research: https://lnkd.in/eknNuN4C ? #NobelPrize #Chemistry #proteins #research #BasicResearch #science #NIH

Here is a digest of #NIAID-supported research presentations from Wednesday, October 9 at #HIVR4P2024. - An #HIV vaccine candidate previously shown to be safe but ineffective demonstrated 86% efficacy in a subset of one study’s participants who had a specific gene called HLA-B*07:02. - A combined analysis of 5 studies showed that intravenous infusion of #HIV broadly neutralizing antibodies for #HIV prevention was safe and infusion-related reactions were uncommon. - Male partners shared reasons for hesitancy over their pregnant partners joining an #HIV prevention study involving the dapivirine vaginal ring and oral pre-exposure prophylaxis. - A nanoparticle #HIV vaccine concept was safe and generated immune responses that showed signs of being able to produce HIV broadly neutralizing antibodies if stimulated further. - A study examining three forms of an mRNA-based #HIV vaccine found that all three forms elicited immune responses, with membrane bound forms showing the broadest response. - An #HIV vaccine concept designed to teach the immune system to target the fusion peptide (FP) on HIV's surface, generated immune responses that showed signs of being able to recognize the HIV fusion peptide if stimulated further. - Early initiation of #AntiretroviralTherapy and #HIV broadly neutralizing antibodies enabled some infant monkeys to remain virally suppressed after therapy was paused. - A multidose #HIV vaccine concept designed to elicit protective immunity prior to adolescence showed signs of generating the first steps of relevant immune responses in infant monkeys. - An mRNA-based #HIV vaccine targeting a site on HIV’s surface stimulated initial immune responses in infant monkeys and these findings will guide the next iteration of a novel HIV vaccine concept. - A study comparing infant and juvenile immune responses to an #HIV vaccine concept found that infant monkeys more frequently generated desired immune responses than juvenile monkeys. - Infusions with 2 different doses of #HIV broadly neutralizing antibodies for #HIVprevention resulted in detectable antibodies in rectal tissue samples of men and women weeks after infusion, suggesting possible durability. - A novel refillable antiretroviral drug implant was found to be safe and capable of delivering one or more drugs. The implant is being studied for delivery of #HIV pre-exposure prophylaxis and #AntiretroviralTherapy. For full text abstracts, visit the conference program: https://lnkd.in/d9PVgniW #HIVR4P2024 #bNAbs #HIV #HIVprevention #PrEP